- Home
- RNG vs IMVT Comparison
RNG vs IMVT Comparison
Compare RNG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNG
- IMVT
- Stock Information
- Founded
- RNG 1999
- IMVT 2018
- Country
- RNG United States
- IMVT United States
- Employees
- RNG N/A
- IMVT N/A
- Industry
- RNG EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNG Technology
- IMVT Health Care
- Exchange
- RNG Nasdaq
- IMVT Nasdaq
- Market Cap
- RNG 2.7B
- IMVT 2.7B
- IPO Year
- RNG 2013
- IMVT N/A
- Fundamental
- Price
- RNG $23.62
- IMVT $15.71
- Analyst Decision
- RNG Buy
- IMVT Buy
- Analyst Count
- RNG 15
- IMVT 11
- Target Price
- RNG $34.00
- IMVT $37.38
- AVG Volume (30 Days)
- RNG 1.5M
- IMVT 1.4M
- Earning Date
- RNG 08-05-2025
- IMVT 08-08-2025
- Dividend Yield
- RNG N/A
- IMVT N/A
- EPS Growth
- RNG N/A
- IMVT N/A
- EPS
- RNG N/A
- IMVT N/A
- Revenue
- RNG $2,428,240,000.00
- IMVT N/A
- Revenue This Year
- RNG $5.82
- IMVT N/A
- Revenue Next Year
- RNG $5.51
- IMVT N/A
- P/E Ratio
- RNG N/A
- IMVT N/A
- Revenue Growth
- RNG 7.78
- IMVT N/A
- 52 Week Low
- RNG $20.59
- IMVT $12.72
- 52 Week High
- RNG $42.19
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- RNG 29.59
- IMVT 38.36
- Support Level
- RNG $26.67
- IMVT $15.31
- Resistance Level
- RNG $27.55
- IMVT $17.12
- Average True Range (ATR)
- RNG 0.90
- IMVT 0.84
- MACD
- RNG -0.33
- IMVT -0.31
- Stochastic Oscillator
- RNG 0.00
- IMVT 10.67
About RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.